Bristol Myers Squibb (BMY) Restructuring Costs (2009 - 2013)
Bristol Myers Squibb (BMY) posted quarterly Restructuring Costs of $33.0 million for Q1 2013, up 50.0% YoY from $22.0 million in Q1 2012, and down 67.96% sequentially from $103.0 million in Q4 2012.
Bristol Myers Squibb (BMY) Restructuring Costs (2009 - 2013) Analysis & Trends
Bristol Myers Squibb has disclosed Restructuring Costs across 5 years of filings, most recently posting $33.0 million for Q1 2013.
- In Q1 2013, Restructuring Costs rose 50.0% year-over-year to $33.0 million; the TTM figure through Mar 2013 stood at $164.0 million (up 137.68% YoY), while the FY2012 annual figure was $174.0 million, up 50.0% from the prior year.
- Restructuring Costs declined to $33.0 million in Q1 2013, from $103.0 million in the prior quarter.
- Over the last five years, Restructuring Costs for BMY reached as high as $103.0 million in Q4 2012 and fell as low as $1.0 million in Q1 2011.
- The 5-year median for Restructuring Costs is $20.0 million (2012), against an average of $27.9 million.
- Annual changes were most pronounced in 2011 — Restructuring Costs sank 90.91% — and 2012, when it surged 2100.0%.
- A 5-year view of Restructuring Costs shows it stood at $35.0 million in 2009, then surged by 80.0% to $63.0 million in 2010, then sank by 61.9% to $24.0 million in 2011, then jumped by 329.17% to $103.0 million in 2012, then sank by 67.96% to $33.0 million in 2013.
- According to Business Quant data, Restructuring Costs over the past three periods registered $33.0 million, $103.0 million, and $8.0 million for Q1 2013, Q4 2012, and Q3 2012 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 33.00 Mn |
| Dec 31, 2012 | 103.00 Mn |
| Sep 30, 2012 | 8.00 Mn |
| Jun 30, 2012 | 20.00 Mn |
| Mar 31, 2012 | 22.00 Mn |
| Dec 31, 2011 | 24.00 Mn |
| Sep 30, 2011 | 8.00 Mn |
| Jun 30, 2011 | 15.00 Mn |
| Mar 31, 2011 | 1.00 Mn |
| Dec 31, 2010 | 63.00 Mn |
| Sep 30, 2010 | 15.00 Mn |
| Jun 30, 2010 | 24.00 Mn |
| Mar 31, 2010 | 11.00 Mn |
| Dec 31, 2009 | 35.00 Mn |
| Sep 30, 2009 | 54.00 Mn |
| Jun 30, 2009 | 19.00 Mn |
| Mar 31, 2009 | 19.00 Mn |